Skip to content

A study on the safety of and immune response to different doses of RSV/hMPV combination and hMPV vaccines in adults

Status
Not yet recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-524456-58-00
Enrollment
464
Registered
2026-06-04
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Syncytial Virus Infections+Metapneumovirus

Interventions

None listed

Sponsors

GlaxoSmithKline Biologicals
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 5, 2026